Sarcomas and DDR-Inhibition; a Neoadjuvant Phase I Combined Modality Study
Latest Information Update: 24 Apr 2024
Price :
$35 *
At a glance
- Drugs AZD 1390 (Primary) ; Durvalumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Acronyms SADDRIN-1
- 19 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Jul 2028.
- 19 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2026.
- 23 Sep 2023 Planned number of patients changed from 15 to 30.